JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
LOS ANGELES, March 10, 2016 -- Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) (“Ritter Pharmaceuticals” or the “Company”), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases, today announced that Michael Step, Chief Executive Officer, will present a corporate overview at the 28th Annual ROTH Conference on Tuesday, March 15, 2016.
Event: 28th Annual ROTH Conference
Date: Tuesday, March 15, 2016
Time: 12:30-1:00 p.m. PT
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company is advancing human gut health research by exploring the metabolic capacity of gut microbiota, and translating the functionality of these microbiome modulators into safe and effective applications. Their lead drug candidate, RP-G28, has the potential to become the first FDA-approved drug for lactose intolerance, a condition that affects more than one billion people worldwide.
Investor Contact: David Burke [email protected] (646) 536-7009
